05/12/22 4:05 PMNasdaq : KNTE earningslow floatKinnate Biopharma Inc. Reports First Quarter 2022 Financial Results and Provides Operational UpdatesInitial monotherapy data from ongoing Phase 1 KN-8701 clinical trial expected in the fourth quarter of 2022 Announces initiation of the combination portion of Phase 1 KN-8701 clinical trial to evaluate its pan-RAF inhibitor, KIN-2787, with binimetinib in NRAS-mutant melanoma First patient dosed inRHEA-AIneutral
04/18/22 8:00 AMNasdaq : KNTE clinical triallow floatKinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidate, KIN-3248Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that theRHEA-AIneutral
04/08/22 4:30 PMNasdaq : KNTE low floatKinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual MeetingKinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceuticalRHEA-AIneutral
03/28/22 4:05 PMNasdaq : KNTE earningslow floatKinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational UpdatesInitiated Phase 1 clinical trial for KIN-3248 in the first quarter of 2022 Initial monotherapy data from the ongoing KN-8701 Phase 1 trial expected in the third quarter of 2022 Initiation of the combination portion of KN-8701 to study KIN-2787 with binimetinib in NRAS-mutant melanoma expected inRHEA-AIneutral
03/08/22 6:00 PMNasdaq : KNTE low floatKinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation at the American Association for Cancer Research Annual MeetingKinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery andRHEA-AIneutral
03/07/22 6:00 AMNasdaq : KNTE low floatKinnate Biopharma Inc. Presents Data from its Real-World Clinico-Genomic Study Collaboration with Tempus at the Virtual ESMO Targeted Anticancer Therapies CongressKinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), aRHEA-AIneutral
02/28/22 4:05 PMNasdaq : KNTE conferenceslow floatKinnate Biopharma Inc. to Participate in the 42nd Annual Cowen Health Care ConferenceKinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that itsRHEA-AIneutral
02/14/22 8:00 AMNasdaq : KNTE low float Kinnate Biopharma Inc. Selected to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer MeetingKinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on theRHEA-AIneutral
02/07/22 4:05 PMNasdaq : KNTE conferenceslow floatKinnate Biopharma Inc. to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceKinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that itsRHEA-AIneutral
01/19/22 4:05 PMNasdaq : KNTE conferencesclinical triallow floatKinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers SymposiumKinnate BiopharmaRHEA-AIneutral